The past few days have seen a few developments on the medicines regulations front, ranging from the release by the MHRA of new guidelines concerning the procedure and requirements for acquiring Marketing Authorisation for e-cig related substances and associated devices, to the full text of the advice from Sir Francis Jacobs QC to ECITA.
We’ve also seen the UK release of the Vype cigalike by British American Tobacco.
In putting this post together, I am mindful of the comments and contributions of others and will seek not to tread on ground pretroddened, except where I can’t really help it. So if you think there are gaps in what I’m covering, that’ll be why.
